Sage Therapeutics (NASDAQ:SAGE)‘s stock had its “outperform” rating restated by equities research analysts at BMO Capital Markets in a research report issued on Thursday, The Fly reports. They presently have a $203.00 price target on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective would indicate a potential upside of 29.90% from the stock’s previous close.

Other analysts also recently issued research reports about the stock. Royal Bank Of Canada dropped their price target on shares of Sage Therapeutics from $145.00 to $137.00 and set an “outperform” rating on the stock in a report on Monday, November 27th. Raymond James Financial raised their price target on shares of Sage Therapeutics to $109.00 and gave the company a “buy” rating in a report on Thursday, November 9th. Chardan Capital raised shares of Sage Therapeutics from a “neutral” rating to a “buy” rating and raised their price target for the company from $60.00 to $140.00 in a report on Friday, November 10th. Needham & Company LLC raised their price target on shares of Sage Therapeutics from $86.00 to $100.00 and gave the company a “buy” rating in a report on Friday, November 10th. Finally, Leerink Swann raised their price target on shares of Sage Therapeutics from $85.00 to $123.00 and gave the company a “positive” rating in a report on Thursday, November 9th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $121.86.

Sage Therapeutics (NASDAQ:SAGE) traded up $64.37 during trading hours on Thursday, reaching $156.27. 8,229,955 shares of the company’s stock were exchanged, compared to its average volume of 548,792. Sage Therapeutics has a 1-year low of $44.55 and a 1-year high of $100.50.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.98) by $0.01. The business’s revenue for the quarter was up .0% compared to the same quarter last year. equities research analysts predict that Sage Therapeutics will post -7.4 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Sage Therapeutics by 11.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,378 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 138 shares during the last quarter. Hershey Trust Co. purchased a new position in shares of Sage Therapeutics in the third quarter worth approximately $118,000. Oppenheimer Asset Management Inc. boosted its holdings in shares of Sage Therapeutics by 412.9% in the third quarter. Oppenheimer Asset Management Inc. now owns 1,944 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 1,565 shares during the last quarter. Turner Investments LLC purchased a new position in shares of Sage Therapeutics in the second quarter worth approximately $159,000. Finally, Dubuque Bank & Trust Co. purchased a new position in shares of Sage Therapeutics in the second quarter worth approximately $167,000. 95.40% of the stock is currently owned by institutional investors.

WARNING: “BMO Capital Markets Reiterates Outperform Rating for Sage Therapeutics (SAGE)” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/12/07/bmo-capital-markets-reiterates-outperform-rating-for-sage-therapeutics-sage.html.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

The Fly

Analyst Recommendations for Sage Therapeutics (NASDAQ:SAGE)

Receive News & Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.